Work

Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in combination with fulvestrant in treatment refractory advanced breast cancer patients.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.1064

Authors: Anna M. Varghese, Kathleen N. Moore, Erika Paige Hamilton, David Michael Hyman, Komal L. Jhaveri, Xuejing Aimee Wang, Sophie Callies, Aaron Alan Fink, Volker Wacheck, Johanna C. Bendell

Institutions: Memorial Sloan Kettering Cancer Center, University of Oklahoma Health Sciences Center, Tennessee Oncology, New York University, Eli Lilly (United States), Eli Lilly (United Kingdom)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2621530879

Cites:

Cited by: 2

Related to: 10